» Articles » PMID: 24621612

DLK1 Promotes Lung Cancer Cell Invasion Through Upregulation of MMP9 Expression Depending on Notch Signaling

Overview
Journal PLoS One
Date 2014 Mar 14
PMID 24621612
Citations 42
Authors
Affiliations
Soon will be listed here.
Abstract

The transmembrane and secreted protein delta-like 1 homolog (DLK1) belongs to the EGF-like family. It is widely accepted that DLK1 plays important roles in regulating cell differentiation, such as adipogenesis and osteogenesis. Aberrant expression of DLK1 has been found in various types of human cancers, including lung cancer. A previous study in this lab has revealed that DLK1 is associated with tumor invasion, although the mechanism is still unknown. To explore the potential effects that DLK1 might have on invasion, DLK1 was overexpressed or knocked down in the human lung cancer cell lines. The protein's influences on cell invasion were subsequently evaluated. A transwell assay showed that DLK1 overexpression significantly promoted cancer cell invasion. Western blotting and gelatin zymography analysis indicated that DLK1 could affect both matrix metalloproteinase-9 (MMP9) expression and its extracellular activity. An analysis of NOTCH1 and HES1 gene expression and Notch intracellular domain (NICD) nuclear translocation during DLK1 stimulation or depletion demonstrated that DLK1 could activate Notch signaling in lung cancer cells. Additionally, the elevated expression of MMP9 induced by DLK1 stimulation could be significantly decreased by inhibiting Notch signaling using γ-secretase inhibitor (GSI). The data presented in this study suggest that DLK1 can promote the invasion of lung cancer cells by upregulating MMP9 expression, which depends on Notch signaling.

Citing Articles

Comprehensive mapping of somatotroph pituitary neuroendocrine tumour heterogeneity using spatial and single-cell transcriptomics.

Wang J, Li X, Guo J, Yuan Z, Tong X, Xiao Z Clin Transl Med. 2024; 14(11):e70090.

PMID: 39548559 PMC: 11567828. DOI: 10.1002/ctm2.70090.


LncRNAs in the Domain Are Essential for Mid-Embryonic Heart Development.

Teng X, He H, Yu H, Zhang X, Xing J, Shen J Int J Mol Sci. 2024; 25(15).

PMID: 39125754 PMC: 11311489. DOI: 10.3390/ijms25158184.


DLK1 overexpression improves sepsis-induced cardiac dysfunction and fibrosis in mice through the TGF-β1/Smad3 signaling pathway and MMPs.

Zeng N, Jian Z, Xu J, Zheng S, Fan Y, Xiao F J Mol Histol. 2023; 54(6):655-664.

PMID: 37759133 DOI: 10.1007/s10735-023-10161-6.


A functional -1562C>T polymorphism, MMP-9 serum levels and nephrolithiasis risk in a southern Chinese population.

Ding Q, Cao C, Shi Y, Fan Z, Li F, Tu W Front Med (Lausanne). 2023; 10:1175798.

PMID: 37332754 PMC: 10272514. DOI: 10.3389/fmed.2023.1175798.


alleviates the progress of hepatocellular carcinoma and type 2 diabetes in mice model interplay of gut microflora, bile acid and NOTCH 1 signaling.

Chen S, Han P, Zhang Q, Liu P, Liu J, Zhao L Front Immunol. 2023; 14:1179014.

PMID: 37234174 PMC: 10206262. DOI: 10.3389/fimmu.2023.1179014.


References
1.
Kim K, Kim J, Wang Y, Sul H . Pref-1 (preadipocyte factor 1) activates the MEK/extracellular signal-regulated kinase pathway to inhibit adipocyte differentiation. Mol Cell Biol. 2007; 27(6):2294-308. PMC: 1820487. DOI: 10.1128/MCB.02207-06. View

2.
Chu D, Zhang Z, Zhou Y, Wang W, Li Y, Zhang H . Notch1 and Notch2 have opposite prognostic effects on patients with colorectal cancer. Ann Oncol. 2011; 22(11):2440-2447. DOI: 10.1093/annonc/mdq776. View

3.
Baladron V, Ruiz-Hidalgo M, Nueda M, Diaz-Guerra M, Garcia-Ramirez J, Bonvini E . dlk acts as a negative regulator of Notch1 activation through interactions with specific EGF-like repeats. Exp Cell Res. 2005; 303(2):343-59. DOI: 10.1016/j.yexcr.2004.10.001. View

4.
Wang Y, Sul H . Pref-1 regulates mesenchymal cell commitment and differentiation through Sox9. Cell Metab. 2009; 9(3):287-302. PMC: 2673480. DOI: 10.1016/j.cmet.2009.01.013. View

5.
Hafeez B, Adhami V, Asim M, Siddiqui I, Bhat K, Zhong W . Targeted knockdown of Notch1 inhibits invasion of human prostate cancer cells concomitant with inhibition of matrix metalloproteinase-9 and urokinase plasminogen activator. Clin Cancer Res. 2009; 15(2):452-9. PMC: 2951134. DOI: 10.1158/1078-0432.CCR-08-1631. View